Powered by

Actinium Successfully Completes First Module of Collaborative Research Program with Astellas; Second Module Initiated

Jan 17, 2019 - PR Newswire

PR Newswire

 Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) announced today that it has successfully completed the first module of its previously announced research and option agreement with Astellas Pharma Inc. Within the collaboration, the Company is using its Actinium Warhead Enabling (AWE) Platform to conjugate and label select Astellas targeting agents with the potent actinium-225 (Ac-225) payload.

"This collaboration represents Actinium and Astellas' shared commitment...